pyrroles has been researched along with Dysplastic Nevus Syndrome, Hereditary in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Blackham, A; Box, J; Demberger, L; Federowicz, B; Friedland, JC; Ginn, S; Horton, M; Knoerzer, D; McIntosh, A; Nair, S; Shapiro, M; Sheikh, H; Stuhlmiller, TJ; Wolfe, Z | 1 |
| Cuozzo, P; Fattorusso, C; Fiore, D; Forte, G; Franceschelli, S; Gazzerro, P; Pascale, M; Proto, MC; Ramunno, A | 1 |
| Adamus, G; Amundson, D; Boon, CJ; Haanen, JB; Jager, MJ; Kapiteijn, EH; Keunen, JE; Luyten, GP; Marinkovic, M; van Dijk, EH; van Herpen, CM | 1 |
1 trial(s) available for pyrroles and Dysplastic Nevus Syndrome, Hereditary
| Article | Year |
|---|---|
Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma.
Topics: Adult; Aged; Autoantibodies; Benzimidazoles; Central Serous Chorioretinopathy; Cross-Sectional Studies; Drug Combinations; Electrooculography; Electroretinography; Eye Proteins; Female; Fluorescein Angiography; Humans; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Prospective Studies; Protein Kinase C; Pyrroles; Quinazolines; Skin Neoplasms; Subretinal Fluid; Tomography, Optical Coherence; Uveal Neoplasms; Visual Acuity | 2015 |
2 other study(ies) available for pyrroles and Dysplastic Nevus Syndrome, Hereditary
| Article | Year |
|---|---|
Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma.
Topics: Aminopyridines; Cell Line, Tumor; Humans; MAP Kinase Signaling System; Melanoma; Melanoma, Cutaneous Malignant; Mitogen-Activated Protein Kinase Kinases; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrroles; Skin Neoplasms | 2022 |
Tetra-substituted pyrrole derivatives act as potent activators of p53 in melanoma cells.
Topics: Apoptosis; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; HSP90 Heat-Shock Proteins; Humans; Imidazoles; Melanoma; Melanoma, Cutaneous Malignant; Mutation; Piperazines; Proto-Oncogene Proteins c-mdm2; Pyrroles; Skin Neoplasms; Transcription, Genetic; Tumor Suppressor Protein p14ARF; Tumor Suppressor Protein p53 | 2020 |